Doryx is a brand name of doxycycline, approved by the FDA in the following formulation(s):
DORYX (doxycycline hyclate - tablet, delayed release; oral)
Manufacturer: MAYNE PHARMA
Approval date: May 6, 2005
Strength(s): EQ 100MG BASE [AB], EQ 75MG BASE [AB]
Manufacturer: MAYNE PHARMA
Approval date: June 20, 2008
Strength(s): EQ 150MG BASE [RLD][AB]
Has a generic version of Doryx been approved?
A generic version of Doryx has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Doryx and have been approved by the FDA:
doxycycline hyclate tablet, delayed release; oral
Manufacturer: ACTAVIS ELIZABETH
Approval date: December 14, 2011
Strength(s): EQ 100MG BASE [AB], EQ 75MG BASE [AB]
Manufacturer: IMPAX LABS INC
Approval date: December 28, 2010
Strength(s): EQ 100MG BASE [AB], EQ 75MG BASE [AB]
Manufacturer: MYLAN
Approval date: December 28, 2010
Strength(s): EQ 100MG BASE [AB], EQ 75MG BASE [AB]
Manufacturer: MYLAN PHARMS INC
Approval date: February 8, 2012
Strength(s): EQ 150MG BASE [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Doryx. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Modified release coated drug preparation
Patent 6,958,161
Issued: October 25, 2005
Inventor(s): Hayes; David & LoPore; Angelo & Lukas; Stefan & Quinn; Eugene
Assignee(s): F H Faulding & Co Limited
A modified release preparation having one or more coated core elements, each core element including an active ingredient and having a modified release coating, wherein a stabilising coat is provided between each core element and its modified release coating so that, upon in vitro dissolution testing, the amount of active ingredient released at any time on a post-storage dissolution profile is within 40 percentage points of the amount of active ingredient released at any time on a pre-storage dissolution profile.
Patent expiration dates:
See also...
- Doryx Delayed-Release Capsules Consumer Information (Wolters Kluwer)
- Doryx Delayed-Release Tablets Consumer Information (Wolters Kluwer)
- Doryx Consumer Information (Cerner Multum)
- Doryx Advanced Consumer Information (Micromedex)
- Doxycycline Consumer Information (Drugs.com)
- Doxycycline Consumer Information (Wolters Kluwer)
- Doxycycline Capsules Consumer Information (Wolters Kluwer)
- Doxycycline Hyclate Consumer Information (Wolters Kluwer)
- Doxycycline Hyclate Delayed-Release Capsules Consumer Information (Wolters Kluwer)
- Doxycycline Hyclate Delayed-Release Tablets Consumer Information (Wolters Kluwer)
- Doxycycline Kit Consumer Information (Wolters Kluwer)
- Doxycycline Monohydrate Consumer Information (Wolters Kluwer)
- Doxycycline Suspension Consumer Information (Wolters Kluwer)
- Doxycycline Syrup Consumer Information (Wolters Kluwer)
- Doxycycline Tablets Consumer Information (Wolters Kluwer)
- Doxycycline with Cleanser Consumer Information (Wolters Kluwer)
- Doxycycline Consumer Information (Cerner Multum)
- Adoxa Pak Advanced Consumer Information (Micromedex)
- Atridox Advanced Consumer Information (Micromedex)
- Vibramycin Hyclate Advanced Consumer Information (Micromedex)
- Doxycycline Advanced Consumer Information (Micromedex)
- Doxycycline Subgingival Advanced Consumer Information (Micromedex)
- Doxycycline AHFS DI Monographs (ASHP)
- Doxycycline Calcium AHFS DI Monographs (ASHP)
- Doxycycline Hyclate AHFS DI Monographs (ASHP)
- Doxycycline Hyclate eent AHFS DI Monographs (ASHP)
- Doxycycline Monohydrate AHFS DI Monographs (ASHP)
